Research Article
Circulating Platelet-Derived Microparticles Associated with Postdischarge Major Adverse Cardiac Events in ST-Elevation Acute Myocardial Infarction
Table 2
Characteristics of subjects with STEMI and their comparison based on the occurrence of 30-day postdischarge MACE.
| | Characteristics | All subjects (n = 81) | 30-day MACE (+) (n = 23) | 30-day MACE (−) (n = 58) | value |
| | Gender (male), n (%) | 75 (92.6) | 21 (91.3) | 54 (93.1) | 0.551 | | Age (years), mean ± SD | 54.4 ± 9.1 | 55.6 ± 7.9 | 54.3 ± 9.2 | 0.594 | | Dyslipidemia, n (%) | 22 (27.2) | 6 (26.1) | 16 (27.6) | 0.891 | | Diabetes mellitus, n (%) | 18(22.2) | 7 (30.4) | 11 (19.0) | 0.263 | | Ischemic heart disease, n (%) | 16 (19.8) | 4 (17.4) | 12 (20.7) | 0.501 | | Hypertension, n (%) | 36 (44.4) | 14 (60.9) | 22 (37.9) | 0.061 | | Current smoker, n (%) | 50 (61.7) | 14 (60.9) | 36 (62.1) | 0.251 | | Onset (hours), median (IQR) | 4.3(3.0–7.0) | 5 (3.0–7.2) | 4.5 (3.0–7.0) | 0.643 | | Systolic BP (mmHg), mean ± SD | 135.3 ± 25.3 | 130.2 ± 18.8 | 136.3 ± 26.1 | 0.368 | | Diastolic BP (mmHg), mean ± SD | 83.7 ± 13.7 | 82.0 ± 13.8 | 83.4 ± 13.9 | 0.702 | | Heart rate (x/min), mean ± SD | 79.1 ± 18.2 | 91.1 ± 19.7 | 76.8 ± 16.2 | 0.002 | | Anterior STEMI, n (%) | 48 (59.3) | 15 (65.2) | 33 (56.9) | 0.492 | | Killip class ≥2 | 11 (13.6) | 11 (47.8) | 0 (0) | <0.001 | | Revascularization | | | | 0.090 | | Primary PCI | 44 (63.8) | 16 (84.2) | 28 (56.0) | | | Fibrinolysis | 25 (36.2) | 3 (15.8) | 22 (44.0) | | | Vessel disease | | | | 0.544 | | 1 vessel disease | 22 (41.5) | 6 (31.6) | 16 (47.1) | | | 2 vessel disease | 16 (30.1) | 6 (31.6) | 10 (29.4) | | | 3 vessel disease | 12 (22.6) | 5 (26.3) | 7 (20.6) | | | Any + left main disease | 3 (5.6) | 2 (10.5) | 1 (2.9) | | | Culprit vessel | | | | 0.261 | | Left anterior descendent | 35 (66.0) | 15 (78.9) | 20 (58.8) | | | Right coronary artery | 16 (30.1) | 4 (21.1) | 12 (35.3) | | | Left circumflexus | 2 (2.5) | 0 (0) | 2 (5.9) | | | Intervention | | | | 0.255 | | Drug-eluting stent | 50 (94.3) | 19 (100.0) | 31 (91.2) | | | Bare metal stent | 3 (5.7) | 0 (0) | 3 (8.8) | | | Haemoglobin (g/dL) | 13.9 ± 1.7 | 13.7 ± 1.7 | 14.0 ± 1.7 | 0.401 | | Leucocytes (×103/mm3) | 13.3 ± 3.5 | 12.9 ± 4.1 | 13.5 ± 3.3 | 0.553 | | Platelets (×103/mm3) | 265.9 ± 80.1 | 265.3 ± 74.4 | 266.2 ± 82.8 | 0.964 | | Creatinine (mg/dL) | 1.2 ± 0.4 | 1.3 ± 0.5 | 1.2 ± 0.4 | 0.497 | | Urea nitrogen (mg/dL) | 15.1 ± 6.2 | 15.5 ± 7.8 | 14.9 ± 5.5 | 0.700 | | Random glucose (mg/dL) | 166.6 ± 73.4 | 185.9 ± 96.3 | 158.4 ± 60.5 | 0.216 | | Clopidogrel | 81 (100) | 17 (100) | 84 (100) | NA | | Acetylsalicylic acid | 81 (100) | 17 (100) | 84 (100) | NA | | ACEI/ARB | 54 (66.7) | 17 (73.9) | 37 (63.8) | 0.384 | | Beta blockers | 51 (63.0) | 18 (78.3) | 33 (56.9) | 0.073 | | Furosemide | 14 (17.3) | 9 (39.1) | 5 (8.6) | 0.001 | | Heparin | 53 (65.4) | 15 (65.2) | 38 (65.5) | 0.980 |
|
|
n = 69 subjects n = 53 subjects. BP: blood pressure; STEMI: ST-elevation myocardial infarction; ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin-receptor blocker; NA: not applicable. |
